The implantable lens maker said it would remain a stand-alone company after its shareholders turned down Alcon’s $1.6 billion ...

STAAR Surgical said shareholders rejected its merger with Alcon, ending the $1.6 billion deal. The eye care company will ...

STAAR Surgical Company (NASDAQ: STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on ...

Staar Surgical (STAA) announced that based on preliminary estimates by Staar’s proxy solicitor, Staar did not receive the necessary stockholder ...

STAAR’s results show a story about timing, cash discipline, and what happens when reported growth finally lines up with ...

Preliminary net sales of $94.7 million, up 6.9% compared to $88.6 million in the prior year period. Preliminary net sales included $25.9 million related to the previously disclosed December 2024 ICL ...

$5 million represents STAAR's highest quarterly ICL sales in U.S. since it obtained FDA approval for EVO ICL in March 2022. Analyst says achieving STAAR Surgical's revenue target for 2026 seems ...

“EVO ICL is the next logical step in refractive innovation. While adoption of any new technology takes time, EVO ICL’s adoption rate has been steadily rising since launch – achieving market leadership ...

GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, ...